Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XBB.1.5-adapted monovalent vaccine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The XBB.1.5-adapted monovalent vaccine is an mRNA-based COVID-19 vaccine specifically designed to target the spike protein of the SARS-CoV-2 Omicron sublineage XBB.1.5. It delivers genetic instructions for the host’s cells to produce the XBB.1.5 spike protein, generating an adaptive immune response—primarily neutralizing antibodies—directed against this variant. This updated formulation improves protection against contemporary Omicron sublineages, including XBB.1.5, EG.5.1, and BA.2.86, and has demonstrated favorable safety and immunogenicity profiles in clinical trial and real-world settings. The vaccine is deployed as a single-dose booster in individuals who previously completed a primary mRNA COVID-19 vaccine series[1][4][5].
- Brand names
- COMIRNATY Omicron XBB.1.5
- Other names
- COMIRNATY Omicron XBB.1.5XBB.1.5-adapted BNT162b2XBB.1.5-adapted COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on XBB.1.5-adapted monovalent vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XBB.1.5-adapted monovalent vaccine.